Metilfenidato en el tratamiento del trastorno de déficit de atención con hiperactividad en pediatría: Monitorización en matrices biológicas

E. Papaseit; O. García-Algar; S. Simó; S. Pichini; M. Farré

doi:10.1016/j.anpedi.2012.08.015

Metilfenidato en el tratamiento del trastorno de déficit de atención con hiperactividad en pediatría: Monitorización en matrices biológicas

E. Papaseit, O. García-Algar, S. Simó, S. Pichini, M. Farré

Research output: Contribution to journal › Article › Research › peer-review

3 Citations (Scopus)

Abstract

Attention-deficit hyperactivity disorder (ADHD) has emerged in the last few years as the most commonly diagnosed and treated psychiatric disorder in the paediatric population. In 1980's, methylphenidate (MFD) a psychomotor stimulant drug, was approved in Spain for the symptomatic therapy of ADHD. Since then, MFD has become one of the most extensively prescribed and studied treatment for ADHD both in children and adults. In this paper, the main pharmacological issues of MFD are reviewed, focusing on its pharmacokinetics in conventional (blood and urine) and non-conventional (hair, oral fluid and sweat) biological matrices, its pharmaceutical preparations, therapeutic levels and side effects.

Original language	English
Pages (from-to)	123.e1-123.e10
Journal	Anales de Pediatria
Volume	78
Issue number	2
DOIs	https://doi.org/10.1016/j.anpedi.2012.08.015
Publication status	Published - 1 Jan 2013

Keywords

Attention deficit and hyperactivity disorder
Dopamine
Methylphenidate
Stimulant
Therapeutic drug monitoring

Access to Document

10.1016/j.anpedi.2012.08.015

Cite this

@article{40ed736a7950404db3df6a38e01c817c,

title = "Metilfenidato en el tratamiento del trastorno de d{\'e}ficit de atenci{\'o}n con hiperactividad en pediatr{\'i}a: Monitorizaci{\'o}n en matrices biol{\'o}gicas",

abstract = "Attention-deficit hyperactivity disorder (ADHD) has emerged in the last few years as the most commonly diagnosed and treated psychiatric disorder in the paediatric population. In 1980's, methylphenidate (MFD) a psychomotor stimulant drug, was approved in Spain for the symptomatic therapy of ADHD. Since then, MFD has become one of the most extensively prescribed and studied treatment for ADHD both in children and adults. In this paper, the main pharmacological issues of MFD are reviewed, focusing on its pharmacokinetics in conventional (blood and urine) and non-conventional (hair, oral fluid and sweat) biological matrices, its pharmaceutical preparations, therapeutic levels and side effects.",

keywords = "Attention deficit and hyperactivity disorder, Dopamine, Methylphenidate, Stimulant, Therapeutic drug monitoring",

author = "E. Papaseit and O. Garc{\'i}a-Algar and S. Sim{\'o} and S. Pichini and M. Farr{\'e}",

year = "2013",

month = jan,

day = "1",

doi = "10.1016/j.anpedi.2012.08.015",

language = "English",

volume = "78",

pages = "123.e1--123.e10",

number = "2",

}

TY - JOUR

T1 - Metilfenidato en el tratamiento del trastorno de déficit de atención con hiperactividad en pediatría: Monitorización en matrices biológicas

AU - Papaseit, E.

AU - García-Algar, O.

AU - Simó, S.

AU - Pichini, S.

AU - Farré, M.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Attention-deficit hyperactivity disorder (ADHD) has emerged in the last few years as the most commonly diagnosed and treated psychiatric disorder in the paediatric population. In 1980's, methylphenidate (MFD) a psychomotor stimulant drug, was approved in Spain for the symptomatic therapy of ADHD. Since then, MFD has become one of the most extensively prescribed and studied treatment for ADHD both in children and adults. In this paper, the main pharmacological issues of MFD are reviewed, focusing on its pharmacokinetics in conventional (blood and urine) and non-conventional (hair, oral fluid and sweat) biological matrices, its pharmaceutical preparations, therapeutic levels and side effects.

AB - Attention-deficit hyperactivity disorder (ADHD) has emerged in the last few years as the most commonly diagnosed and treated psychiatric disorder in the paediatric population. In 1980's, methylphenidate (MFD) a psychomotor stimulant drug, was approved in Spain for the symptomatic therapy of ADHD. Since then, MFD has become one of the most extensively prescribed and studied treatment for ADHD both in children and adults. In this paper, the main pharmacological issues of MFD are reviewed, focusing on its pharmacokinetics in conventional (blood and urine) and non-conventional (hair, oral fluid and sweat) biological matrices, its pharmaceutical preparations, therapeutic levels and side effects.

KW - Attention deficit and hyperactivity disorder

KW - Dopamine

KW - Methylphenidate

KW - Stimulant

KW - Therapeutic drug monitoring

U2 - 10.1016/j.anpedi.2012.08.015

DO - 10.1016/j.anpedi.2012.08.015

M3 - Article

SN - 1695-4033

VL - 78

SP - 123.e1-123.e10

JO - Anales de Pediatria

JF - Anales de Pediatria

IS - 2

ER -

Metilfenidato en el tratamiento del trastorno de déficit de atención con hiperactividad en pediatría: Monitorización en matrices biológicas

Abstract

Keywords

Access to Document

Fingerprint

Cite this